{"groups":[{"description":"Participants with rCC/mCC were administered tisotumab vedotin 2.0 milligram per kilogram (mg/kg) as an intravenous (IV) infusion once every 3 weeks (Q3W).","id":"FG000","title":"Tisotumab Vedotin"},{"description":"Participants with rCC/mCC were treated with investigator's choice of chemotherapy which included either topotecan 1 or 1.25 milligram per meter square \\[mg/m\\^2\\] IV on Days 1 to 5, every 21 days or vinorelbine 30 mg/m\\^2 IV on Days 1 and 8, every 21 days or gemcitabine 1000 mg/m\\^2 IV on Days 1 and 8, every 21 days or irinotecan 100 or 125 mg/m\\^2 IV weekly for 28 days, every 42 days or pemetrexed 500 mg/m\\^2 on Day 1, every 21 days.","id":"FG001","title":"Chemotherapy"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"17"},{"groupId":"FG001","numSubjects":"23"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"4"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"122"},{"groupId":"FG001","numSubjects":"91"}],"type":"On-going in study"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"253"},{"groupId":"FG001","numSubjects":"249"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"250"},{"groupId":"FG001","numSubjects":"239"}],"type":"Treated"},{"achievements":[{"comment":"Completers include participants who died from any cause.","groupId":"FG000","numSubjects":"114"},{"comment":"Completers include participants who died from any cause.","groupId":"FG001","numSubjects":"131"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"139"},{"groupId":"FG001","numSubjects":"118"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}],"preAssignmentDetails":"A total of 660 participants were screened of which 158 participants failed screening and 502 participants were enrolled in the study.","recruitmentDetails":"Participants with recurrent/metastatic cervical cancer (rCC/mCC) who received 1 or 2 prior lines of systemic therapy for their recurrent or metastatic disease were included."}